Citizens Financial Group Inc RI decreased its position in Boston Scientific (NYSE:BSX) by 3.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 229,442 shares of the medical equipment provider’s stock after selling 9,095 shares during the quarter. Citizens Financial Group Inc RI’s holdings in Boston Scientific were worth $6,268,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Truewealth LLC purchased a new position in Boston Scientific in the fourth quarter valued at approximately $116,000. Icon Wealth Partners LLC purchased a new position in Boston Scientific in the fourth quarter valued at approximately $117,000. Delpha Capital Management LLC purchased a new position in Boston Scientific in the fourth quarter valued at approximately $135,000. Alps Advisors Inc. purchased a new position in Boston Scientific in the first quarter valued at approximately $200,000. Finally, Elgethun Capital Management purchased a new position in Boston Scientific in the first quarter valued at approximately $204,000. 89.38% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Boston Scientific opened at $30.39 on Friday, according to MarketBeat. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.59 and a current ratio of 0.82. The company has a market cap of $41.67 billion, a PE ratio of 24.12, a price-to-earnings-growth ratio of 2.15 and a beta of 0.81. Boston Scientific has a 12-month low of $24.54 and a 12-month high of $31.02.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 25th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.01. The business had revenue of $2.38 billion for the quarter, compared to analyst estimates of $2.34 billion. Boston Scientific had a net margin of 1.21% and a return on equity of 25.10%. The company’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share. analysts anticipate that Boston Scientific will post 1.39 earnings per share for the current year.

In related news, SVP Arthur C. Butcher sold 7,500 shares of the stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $30.06, for a total transaction of $225,450.00. Following the completion of the sale, the senior vice president now directly owns 12,484 shares of the company’s stock, valued at $375,269.04. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP John Bradley Sorenson sold 1,950 shares of the stock in a transaction on Monday, March 5th. The stock was sold at an average price of $27.43, for a total value of $53,488.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 175,733 shares of company stock valued at $5,045,163. Corporate insiders own 0.73% of the company’s stock.

Several equities analysts have commented on BSX shares. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 price target on shares of Boston Scientific in a research note on Tuesday, March 27th. Piper Jaffray Companies started coverage on shares of Boston Scientific in a research note on Friday, February 23rd. They issued an “overweight” rating and a $31.00 price target on the stock. Morgan Stanley increased their price target on shares of Boston Scientific from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Monday, March 19th. Royal Bank of Canada reiterated a “top pick” rating and issued a $32.00 price target on shares of Boston Scientific in a research note on Monday, March 5th. Finally, TheStreet lowered shares of Boston Scientific from a “b” rating to a “c” rating in a research note on Monday, March 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $32.23.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.